Trial Profile
A multicenter, randomized, double-blind study comparing the clinical effects of intravenous montelukast with placebo in patients with acute asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Montelukast (Primary)
- Indications Acute asthma
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Feb 2010 Results published in Journal of Allergy and Clinical Immunology.
- 01 Feb 2010 Primary endpoint 'Forced expiratory volume in 1 second' has been met.
- 28 Jul 2008 Status changed from in progress to completed, as reported on clinicaltrials.gov